{"id":3917,"date":"2019-01-10T16:02:42","date_gmt":"2019-01-10T10:32:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3917"},"modified":"2024-09-18T13:38:30","modified_gmt":"2024-09-18T08:08:30","slug":"the-business-cocktail-51","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51","title":{"rendered":"Apollomics raises; Pear Therapeutics raises $64M; Lilly to acquire Loxo"},"content":{"rendered":"\n<p><strong>Apollomics raises USD 100 Million for funding\nof transpacific cancer R&amp;D plan<\/strong><\/p>\n\n\n\n<p class=\"has-text-color has-background has-very-dark-gray-color has-light-green-cyan-background-color\"><strong>Apollomics <\/strong>has&nbsp;raised&nbsp;<strong>USD 100 million<\/strong> for funding an <strong>oncology <\/strong>clinical trial program. The <strong>series B round<\/strong> sets Apollomics to progress its <strong>c-Met inhibitor <\/strong>and pipeline of other clinical-phase assets. <strong>OrbiMed<\/strong> Asia-backed Apollomics has developed a pipeline of small molecules and <strong>monoclonal antibodies<\/strong>. &nbsp;Apollomics has raised USD 100 million in a series B.<\/p>\n\n\n\n<p><strong>Pear Therapeutics raises USD 64 Million<\/strong><\/p>\n\n\n\n<p class=\"has-background has-light-green-cyan-background-color\"><strong>San Francisco based Pear Therapeutics<\/strong> has raised <strong>USD 64 million<\/strong> for its prescription software to treat<strong> opioid <a href=\"https:\/\/www.delveinsight.com\/report-store\/binge-eating-disorders-market\">disorder<\/a><\/strong>. The reSET-O prescription digital therapeutic for opioid use disorder consists of a 12-week cognitive behavioral therapy program intended to be used alongside outpatient treatment. <\/p>\n\n\n\n<p><strong>Eli Lilly to<\/strong> <strong>acquire Loxo Oncology for USD 8 Billion<\/strong><\/p>\n\n\n\n<p class=\"has-background has-light-green-cyan-background-color\">The <strong>Stamford, Connecticut-based biopharma, Eli Lilly<\/strong> will acquire <strong>Loxo Oncology<\/strong> for <strong>USD 8 billion<\/strong>. Loxo quickly flourished in value since going public from USD 200 million to this USD 8 billion agreement. The biopharma got its first U.S. approval for its cancer drug <strong>Vitrakvi<\/strong> that was developed with its partner <strong>Bayer<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apollomics raises USD 100 Million for funding of transpacific cancer R&amp;D plan Apollomics has&nbsp;raised&nbsp;USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apollomics has developed a pipeline of small molecules and monoclonal antibodies. &nbsp;Apollomics has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3918,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2389,107,228,2396,403,427,2393,2391,2392,2394],"industry":[17225],"therapeutic_areas":[17228,17278],"class_list":["post-3917","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-apollomics","tag-bayer","tag-eli-lilly","tag-loxo-oncology","tag-monoclonal-antibodies","tag-oncology","tag-opioid-disorder","tag-orbimed","tag-pear-therapeutics","tag-stamford","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Apollomics raises $100M; Pear&#039;s bags $64M; Lilly to buy Loxo Oncology<\/title>\n<meta name=\"description\" content=\"Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apollomics raises $100M; Pear&#039;s bags $64M; Lilly to buy Loxo Oncology\" \/>\n<meta property=\"og:description\" content=\"Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-10T10:32:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T08:08:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apollomics raises $100M; Pear's bags $64M; Lilly to buy Loxo Oncology","description":"Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51","og_locale":"en_US","og_type":"article","og_title":"Apollomics raises $100M; Pear's bags $64M; Lilly to buy Loxo Oncology","og_description":"Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-10T10:32:42+00:00","article_modified_time":"2024-09-18T08:08:30+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51","name":"Apollomics raises $100M; Pear's bags $64M; Lilly to buy Loxo Oncology","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc.jpg","datePublished":"2019-01-10T10:32:42+00:00","dateModified":"2024-09-18T08:08:30+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-51#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc.jpg","width":1920,"height":1080,"caption":"Neurogene"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/09021831\/bus-coc-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Apollomics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Loxo Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">monoclonal antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">opioid disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">OrbiMed<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pear Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stamford<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Apollomics<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Loxo Oncology<\/span>","<span class=\"advgb-post-tax-term\">monoclonal antibodies<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">opioid disorder<\/span>","<span class=\"advgb-post-tax-term\">OrbiMed<\/span>","<span class=\"advgb-post-tax-term\">Pear Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Stamford<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jan 10, 2019","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jan 10, 2019 4:02 pm","modified":"Updated on Sep 18, 2024 1:38 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3917"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3917\/revisions"}],"predecessor-version":[{"id":29606,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3917\/revisions\/29606"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3918"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3917"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3917"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}